| Isoniazid, pyrazinamide, ethambutol |
Any |
|
| Rifampicin (daily 10 mg/kg) (e.g., 4R, 3HR, RHZE) |
Any NRTI (FTC, likely TAF) |
RIFT—No effect of RIF on emtricitabine; TAF exposure reduced but intracellular tenofovir-DP concentrations remained over × 4 higher than with TDF [48] |
|
EFV 600 mg daily (plus TDF/FTC) |
STRIDE—Slightly higher EFV exposures with RIF, therefore no weight-based EFV adjustment needed [49] |
|
EFV 400 mg daily (with HR) |
Among patients with HIV administered 12 weeks of HR, EFV exposures were not significantly affected [50] |
|
DTG 50 mg twice daily |
INSPIRING—Among patients with HIV receiving HRZE, twice daily DTG safe and effective [51] |
|
RAL 800 mg twice daily |
Reflate TB—Standard RAL dosing (400 mg twice daily) saw only small reduction in exposures (31%) but given concern about narrow RAL therapeutic window concluded that 800 mg twice daily dosing likely preferred [52] |
| Rifapentine (weekly 900 mg) (e.g., 3HP) |
EFV 600 mg daily (plus FTC, TDF) |
Rpt for 3 weeks in patients with HIV on Atripla showed no significant effect on any ART component [53] |
|
DTG 50 mg daily |
Though serious hypersensitivity reaction seen in health volunteer study of DTG plus once weekly ENH-Rpt [54], this was not seen in patients with HIV (DOLPHIN). 3HP increased DTG clearance but not enough to require dose adjustment [55] |
|
RAL 400 mg twice daily |
Among healthy volunteers, receiving RAL plus Rpt 900 mg once weekly for 3 weeks, RAL exposures significantly increased but were well-tolerated [56] |
| Rifapentine (daily 450 or 600 mg) (e.g., 1HP) |
EFV 600 mg daily |
BRIEF-TB—No meaningful reduction in EFV concentrations or virologic suppression [57] |
| Rifapentine high dose (1200 mg daily) (e.g., Rpt-HZE) |
EFV 600 mg daily |
Per recent presentation from TBTC 31/ACTG 5349, only slight reduction in EFV clearance, no effect on virologic suppression, no need for dose adjustment [58] |
| Bedaquiline (e.g., BPaL) |
Nevirapine |
Healthy volunteer study of BDQ plus nevirapine or LPV/r showed no significant effect of or on NVP PK, but LPV/r decreased clearance of BDQ and M2 metabolite by 3% and 58%, raising concerns about co-administration [59] Confirmed in patients with HIV and drug-resistant TB, suggesting dose reduction of BDQ may be necessary with LPV/r [60] |
|
(EFV 600 mg daily) |
Healthy volunteers received daily EFV followed by single dose BDQ 400 without significant impact on BDQ exposures [61], however subsequent modeling suggested 50% reduction in BDQ exposures with EFV [62] |
| Pretomanid (e.g., BPaL) |
EFV |
Pretomanid AUC minimally reduced (35%) [63] |
|
LPV/r |
Pretomanid AUC minimally reduced (17%) [63] |
